




The relative strengths and weaknesses of NRX Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NRX Pharmaceuticals Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 2.9% points. The greatest weakness of NRX Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 34%, being 179% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	6,884
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,048
Liabilities, Non-Current	0
Other Assets	431
Other Compr. Net Income	-6.0
Other Expenses	259
Other Liabilities	0
Other Net Income	-2,313
Other Revenues	0
Property and Equipment	0
Research and Development	13,371
Selling, General and Administrative Expense	14,216

Output Variable	Value in 1000 USD
Assets	7,315
Liabilities	19,048
Expenses	27,846
Revenues	0
Stockholders Equity	-11,733
Net Income	-30,159
Comprehensive Net Income	-30,162
BaseVar	28,264
ECR before LimitedLiability	-423%
Economic Capital Ratio	34%